259 related articles for article (PubMed ID: 19035292)
1. Increased glutathione level is not involved in enhanced bleomycin sensitivity in cisplatin-resistant 2780CP cells.
Tanaka T; Kurokawa H; Matsuno K; Matsumoto S; Hayashida Y
Anticancer Res; 2008; 28(5A):2663-8. PubMed ID: 19035292
[TBL] [Abstract][Full Text] [Related]
2. Pretreatment with 5-fluorouracil enhances cytotoxicity and retention of DNA-bound platinum in a cisplatin resistant human ovarian cancer cell line.
Tanaka T; Masuda H; Naito M; Tamai H
Anticancer Res; 2001; 21(4A):2463-9. PubMed ID: 11724308
[TBL] [Abstract][Full Text] [Related]
3. Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin.
Lau DH; Lewis AD; Ehsan MN; Sikic BI
Cancer Res; 1991 Oct; 51(19):5181-7. PubMed ID: 1717140
[TBL] [Abstract][Full Text] [Related]
4. Independent pathways of p53 induction by cisplatin and X-rays in a cisplatin-resistant ovarian tumor cell line.
Siddik ZH; Mims B; Lozano G; Thai G
Cancer Res; 1998 Feb; 58(4):698-703. PubMed ID: 9485023
[TBL] [Abstract][Full Text] [Related]
5. Radiation survival parameters of antineoplastic drug-sensitive and -resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine.
Louie KG; Behrens BC; Kinsella TJ; Hamilton TC; Grotzinger KR; McKoy WM; Winker MA; Ozols RF
Cancer Res; 1985 May; 45(5):2110-5. PubMed ID: 3986765
[TBL] [Abstract][Full Text] [Related]
6. Modulation of cisplatin resistance in acquired-resistant nonsmall cell lung cancer cells.
Lai SL; Hwang J; Perng RP; Whang-Peng J
Oncol Res; 1995; 7(1):31-8. PubMed ID: 7549042
[TBL] [Abstract][Full Text] [Related]
7. Brostallicin, a novel anticancer agent whose activity is enhanced upon binding to glutathione.
Geroni C; Marchini S; Cozzi P; Galliera E; Ragg E; Colombo T; Battaglia R; Howard M; D'Incalci M; Broggini M
Cancer Res; 2002 Apr; 62(8):2332-6. PubMed ID: 11956092
[TBL] [Abstract][Full Text] [Related]
8. Augmentation of transport for cisplatin-glutathione adduct in cisplatin-resistant cancer cells.
Goto S; Yoshida K; Morikawa T; Urata Y; Suzuki K; Kondo T
Cancer Res; 1995 Oct; 55(19):4297-301. PubMed ID: 7671239
[TBL] [Abstract][Full Text] [Related]
9. Rapid development of drug resistance in human ovarian tumor xenografts after a single treatment with melphalan in Vivo.
Caffrey PB; Zhang Y; Frenkel GD
Anticancer Res; 1998; 18(4C):3021-5. PubMed ID: 9713503
[TBL] [Abstract][Full Text] [Related]
10. High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro.
Kozubík A; Horváth V; Svihálková-Sindlerová L; Soucek K; Hofmanová J; Sova P; Kroutil A; Zák F; Mistr A; Turánek J
Biochem Pharmacol; 2005 Feb; 69(3):373-83. PubMed ID: 15652229
[TBL] [Abstract][Full Text] [Related]
11. Cellular pharmacology of liposomal cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum(II) in A2780/S and A2780/PDD cells.
Han I; Ling YH; al-Baker S; Khokhar AR; Perez-Soler R
Cancer Res; 1993 Oct; 53(20):4913-9. PubMed ID: 8402681
[TBL] [Abstract][Full Text] [Related]
12. Augmentation of cisplatin (DDP) cytotoxicity in vivo by DL-buthionine sulfoximine (BSO) in DDP-sensitive and-resistant rat ovarian tumors and its relation to DNA interstrand cross links.
Chen G; Zeller WJ
Anticancer Res; 1991; 11(6):2231-7. PubMed ID: 1776864
[TBL] [Abstract][Full Text] [Related]
13. Protein kinase C inhibitor Gö6976 augments caffeine-induced reversal of chemoresistance to cis-diamminedichloroplatinum-II (CDDP) in a human ovarian cancer model.
Qamar L; Davis R; Anwar A; Behbakht K
Gynecol Oncol; 2008 Sep; 110(3):425-31. PubMed ID: 18619662
[TBL] [Abstract][Full Text] [Related]
14. Cell cycle perturbations in cisplatin-sensitive and resistant human ovarian carcinoma cells following treatment with cisplatin and low dose rate irradiation.
Wilkins DE; Ng CE; Raaphorst GP
Cancer Chemother Pharmacol; 1997; 40(2):159-66. PubMed ID: 9182838
[TBL] [Abstract][Full Text] [Related]
15. Effect of lung resistance-related protein on the resistance to cisplatin in human ovarian cancer cell lines.
Wang W; Ke S; Chen G; Gao Q; Wu S; Wang S; Zhou J; Yang X; Lu Y; Ma D
Oncol Rep; 2004 Dec; 12(6):1365-70. PubMed ID: 15547764
[TBL] [Abstract][Full Text] [Related]
16. Platinum(IV) complex with adamantylamine overcomes intrinsic resistance to cisplatin in ovarian cancer cells.
Horváth V; Blanárová O; Svihálková-Sindlerová L; Soucek K; Hofmanová J; Sova P; Kroutil A; Fedorocko P; Kozubík A
Gynecol Oncol; 2006 Jul; 102(1):32-40. PubMed ID: 16364413
[TBL] [Abstract][Full Text] [Related]
17. Collateral susceptibility of adriamycin-, melphalan- and cisplatin-resistant human ovarian tumor cells to bleomycin.
Tsuruo T; Hamilton TC; Louie KG; Behrens BC; Young RC; Ozols RF
Jpn J Cancer Res; 1986 Sep; 77(9):941-5. PubMed ID: 2429947
[TBL] [Abstract][Full Text] [Related]
18. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
Samimi G; Kishimoto S; Manorek G; Breaux JK; Howell SB
Cancer Chemother Pharmacol; 2007 Feb; 59(3):301-12. PubMed ID: 16770583
[TBL] [Abstract][Full Text] [Related]
19. The role of glutathione (GSH) in determining sensitivity to platinum drugs in vivo in platinum-sensitive and -resistant murine leukaemia and plasmacytoma and human ovarian carcinoma xenografts.
Goddard P; Valenti M; Kelland LR
Anticancer Res; 1994; 14(3A):1065-70. PubMed ID: 8074451
[TBL] [Abstract][Full Text] [Related]
20. [Potentiation of cisplatin sensitivity of cisplatin-resistant human ovarian cancer cell lines by L-buthionine-S,R-sulfoximine].
Kudoh K; Kita T; Hirata J; Ishii K; Hiramatsu H; Kikuchi Y; Nagata I
Nihon Sanka Fujinka Gakkai Zasshi; 1994 Jun; 46(6):525-32. PubMed ID: 8040625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
